Revolution Medicines, Inc. EPS (Diluted) decreased by 20.5% to $-2.29 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 102.7%, from $-1.13 to $-2.29. Over 4 years (FY 2021 to FY 2025), EPS (Diluted) shows a downward trend with a 23.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher values indicate stronger profitability even when accounting for potential share dilution.
Calculated by dividing net income by the weighted-average number of common shares outstanding, assuming the conversion o...
Used by all public companies to provide a realistic view of earnings per share for investors.
eps_diluted| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$0.60 | -$0.72 | -$0.72 | -$0.78 | -$0.82 | -$0.87 | -$0.61 | -$0.72 | -$0.92 | -$0.99 | -$1.23 | -$0.70 | -$0.81 | -$0.94 | -$1.13 | -$1.13 | -$1.31 | -$1.61 | -$1.90 | -$2.29 |
| QoQ Change | — | -20.0% | +0.0% | -8.3% | -5.1% | -6.1% | +29.9% | -18.0% | -27.8% | -7.6% | -24.2% | +43.1% | -15.7% | -16.0% | -20.2% | +0.0% | -15.9% | -22.9% | -18.0% | -20.5% |
| YoY Change | — | — | — | — | -36.7% | -20.8% | +15.3% | +7.7% | -12.2% | -13.8% | -101.6% | +2.8% | +12.0% | +5.1% | +8.1% | -61.4% | -61.7% | -71.3% | -68.1% | -102.7% |